Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Colorcon
Boehringer Ingelheim
Merck
McKesson

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYLERAN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Myleran

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01049854 CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Active, not recruiting New York Medical College Phase 2 2011-09-01 CD34+ stem cell selection in children, adolescents and young adults receiving partially matched family donor or matched unrelated adult donor allogeneic bone marrow or peripheral blood stem cell transplant will be safe and well tolerated and be associated with a low incidence of serious (Grade III/IV) acute and chronic graft versus host disease (GVHD).
NCT01387763 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting Thomas Stauffer Larsen Phase 3 2012-01-01 The purpose of the study is to compare the efficacy and toxicity including quality of life of two types of low-dose interferon alpha compounds (PegIntron and Pegasys) with hydroxyurea (Hydrea), and to investigate the occurence of neutralizing antibodies against recombinant interferon.
NCT01499147 Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies Completed University of Illinois at Chicago N/A 2000-02-01 New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past several years, the investigators have evaluated several new conditioning regimens that incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic activity with alkylating agents. Recent data have suggested that fludarabine may be used in combination with standard doses of oral or IV busulfan, thus reducing the toxicity previously observed with cyclophosphamide/ busulfan regimens.
NCT03096782 Cord Blood (CB) Ex-vivo Mesenchymal Stem Cell (MSC) Expansion + Fucosylation Not yet recruiting Mesoblast, Inc. Phase 2 2017-06-01 The goal of this clinical research study is to learn if giving 1 unit of expanded cord blood combined with 1 unit of non-expanded cord blood to a patient with leukemia or lymphoma can help the transplant to "take" faster. The safety of this combination will also be studied. Chemotherapy and/or 1 dose of radiation therapy will also be given before the transplant.
NCT03096782 Cord Blood (CB) Ex-vivo Mesenchymal Stem Cell (MSC) Expansion + Fucosylation Not yet recruiting M.D. Anderson Cancer Center Phase 2 2017-06-01 The goal of this clinical research study is to learn if giving 1 unit of expanded cord blood combined with 1 unit of non-expanded cord blood to a patient with leukemia or lymphoma can help the transplant to "take" faster. The safety of this combination will also be studied. Chemotherapy and/or 1 dose of radiation therapy will also be given before the transplant.
NCT03126916 Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Not yet recruiting National Cancer Institute (NCI) Phase 3 2017-08-01 This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
NCT03126916 Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Not yet recruiting Children's Oncology Group Phase 3 2017-08-01 This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Myleran

Condition Name

Condition Name for Myleran
Intervention Trials
Acute Myeloid Leukemia 3
Myelodysplastic Syndrome 2
Myeloproliferative Neoplasm 2
Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Myleran
Intervention Trials
Leukemia, Myeloid 6
Leukemia 6
Leukemia, Myeloid, Acute 6
Primary Myelofibrosis 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Myleran

Trials by Country

Trials by Country for Myleran
Location Trials
United States 13
Mexico 1
Denmark 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Myleran
Location Trials
Texas 3
Washington 2
California 2
Massachusetts 1
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Myleran

Clinical Trial Phase

Clinical Trial Phase for Myleran
Clinical Trial Phase Trials
Phase 3 2
Phase 2 6
Phase 1/Phase 2 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Myleran
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 6
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Myleran

Sponsor Name

Sponsor Name for Myleran
Sponsor Trials
National Cancer Institute (NCI) 5
M.D. Anderson Cancer Center 3
Fred Hutchinson Cancer Research Center 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Myleran
Sponsor Trials
Other 16
NIH 5
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Express Scripts
Moodys
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.